Fluoroquinolones versus trimethoprim-sulfamethoxazole for the treatment of Stenotrophomonas maltophilia infections: a systematic review and meta-analysis
- Authors
- Ko, JH[Ko, J-H.]; Kang, CI[Kang, C-I.]; Cornejo-Juarez, P[Cornejo-Juarez, P.]; Yeh, KM[Yeh, K-M.]; Wang, CH[Wang, C-H.]; Cho, SY[Cho, S. Y.]; Gozel, MG[Gozel, M. G.]; Kim, SH[Kim, S-H.]; Hsueh, PR[Hsueh, P-R.]; Sekiya, N[Sekiya, N.]; Matsumura, Y[Matsumura, Y.]; Lee, DG[Lee, D-G.]; Cho, SY[Cho, S-Y.]; Shiratori, S[Shiratori, S.]; Kim, YJ[Kim, Y-J.]; Chung, DR[Chung, D. R.]; Peck, KR[Peck, K. R.]
- Issue Date
- May-2019
- Publisher
- ELSEVIER SCI LTD
- Keywords
- Fluoroquinolone; Meta-analysis; Stenotrophomonas maltophilia; Systematic review; Trimethoprim-sulfamethoxazole
- Citation
- CLINICAL MICROBIOLOGY AND INFECTION, v.25, no.5, pp.546 - 554
- Indexed
- SCIE
SCOPUS
- Journal Title
- CLINICAL MICROBIOLOGY AND INFECTION
- Volume
- 25
- Number
- 5
- Start Page
- 546
- End Page
- 554
- URI
- https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/10058
- DOI
- 10.1016/j.cmi.2018.11.008
- ISSN
- 1198-743X
- Abstract
- Background: Fluoroquinolones are a popular alternative to trimethoprim-sulfamethoxazole for Stenotrophomonas maltophilia infections. Objectives: To compare the effects of fluoroquinolones and trimethoprim-sulfamethoxazole on mortality of S. maltophilia infections. Data sources: PubMed and EMBASE. Study eligibility criteria: Clinical studies reporting mortality outcomes of S. maltophilia infections. Participants: Patients with clinical infections caused by S. maltophilia. Interventions: Fluoroquinolone monotherapy in comparison with trimethoprim-sulfamethoxazole monotherapy. Methods: Systematic review with meta-analysis technique. Results: Seven retrospective cohort and seven caseecontrol studies were included. Three cohort studies were designed to compare the two drugs, whereas others had other purposes. A total of 663 patients were identified, 332 of which were treated with trimethoprim-sulfamethoxazole (50.1%) and 331 with fluoroquinolones (49.9%). Three cohort studies were designed to compare the effect of the two drugs, whereas the others had other purposes. Levofloxacin was most frequently used among fluoroquinolones (187/331, 56.5%), followed by ciprofloxacin (114/331, 34.4%). The overall mortality rate was 29.6%. Using pooled ORs for the mortality of each study, fluoroquinolone treatment (OR 0.62, 95% CI 0.39-0.99) was associated with survival benefit over trimethoprim-sulfamethoxazole treatment, with low heterogeneity (I-2 = 18%). Specific fluoroquinolones such as ciprofloxacin (OR 0.44, 95% CI 0.17-1.12) and levofloxacin (OR 0.78, 95% CI 0.48-1.26) did not show a significant difference in comparison with trimethoprim-sulfamethoxazole. In the sub-group analyses of adult and bacteraemic patients, significant differences in mortality were not observed between fluoroquinolones and trimethoprim-sulfamethoxazole. Conclusions: Based on a meta-analysis of non-randomized studies, fluoroquinolones demonstrated comparable effects on mortality of S. maltophilia infection to trimethoprim-sulfamethoxazole, supporting the use of fluoroquinolones in clinical S. maltophilia infections. Although the pooled analysis of overall studies favoured fluoroquinolones over trimethoprim-sulfamethoxazole, the studies included were observational, and sub-group analyses of certain fluoroquinolone agents did not show statistical differences with trimethoprim-sulfamethoxazole. Randomized clinical studies are needed to address these issues. (C) 2018 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Medicine > Department of Medicine > 1. Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.bwise.kr/skku/handle/2021.sw.skku/10058)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.